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Background: MicroRNAs (miRNAs) are non-uniformly distributed in genomes and ~30% of the miRNAs in the
human genome are clustered. In this study we have focused on the imprinted miRNA cluster miR-379/miR-656 on
14q32.31 (hereafter C14) to test their coordinated function. We have analyzed expression profile of >1000 human
miRNAs in >1400 samples representing seven different human tissue types obtained from cancer patients along
with matched and unmatched controls.
Results: We found 68% of the miRNAs in this cluster to be significantly downregulated in glioblastoma multiforme
(GBM), 61% downregulated in kidney renal clear cell carcinoma (KIRC), 46% in breast invasive carcinoma (BRCA) and
14% in ovarian serous cystadenocarcinoma (OV). On a genome-wide scale C14 miRNAs accounted for 12-30% of
the total downregulated miRNAs in different cancers. Pathway enrichment for the predicted targets of C14 miRNA
was significant for cancer pathways, especially Glioma (p< 3.77x10-6, FDR<0.005). The observed downregulation was
confirmed in GBM patients by real-time PCR, where 79% of C14 miRNAs (34/43) showed downregulation. In GBM
samples, hypermethylation at C14 locus (p<0.003) and downregulation of MEF2, a crucial transcription factor for the
cluster was observed which likely contribute to the observed downregulation of the entire miRNA cluster.
Conclusion: We provide compelling evidence that the entire C14 miRNA cluster is a tumor suppressor locus
involved in multiple cancers, especially in GBM, and points toward a general mechanism of coordinated function
for clustered miRNAs.
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MicroRNAs are non-randomly distributed across the
human genome in clusters where ~30% of them are located
within 3 Kb distance from another miRNA [1]. MiRNAs
within 50 Kb are reported to be highly correlated in
expression across 24 different human organs [2]. Several
studies have supported the notion that clustered miRNAs
are processed as a single polycistronic transcript [3-6].
Literature evidence indicated that clustered microRNAs
are functionally related by targeting the same gene or a* Correspondence: arijit@igib.in
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reproduction in any medium, provided the orgroup of functionally related genes in the same pathway
[7-10]. He et al. had proposed the presence of clustered
miRNAs to be a pre-requisite for the coordinated control
of related biological processes. Their results indicate
that non-coding RNAs might act as integral parts of
the molecular architecture of oncogene and tumor
suppressor networks, establishing the role of oncomiR-1
(mir-17–92 cluster) in lymphomas [11].
One of the largest human miRNA clusters, namely,
miR-379/miR-656 on chromosome 14q32.31 [hereafter
C14] is encompassed in the conserved imprinted locus
DLK1-DIO3 and is unique to the placental mammal
lineage with enriched expression in brain [12]. This cluster
spanning ~55 Kb on the genome is devoid of protein
coding genes as well as repetitive sequences and harbors
52 mature miRNAs. The polycistronic nature of thisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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factor was demonstrated in rat neurons. Mef2 binding
site is highly conserved within the mammalian lineage
including human [13]. Recently, independent studies
comparing genome-wide miRNA expression differences
reported both up- and downregulation of individual C14
miRNAs in various human diseases including cancer.
While an upregulation was reported for hepatocellular
carcinoma [14], downregulation was observed in case of
gastrointestinal stromal tumors [15]. Eight miRNAs from
C14 were proposed to function as tumor suppressor gene
in epithelial ovarian cancer [16]. However, co-ordinated
function of these clustered miRNA in human diseases
and the plausible underlying mechanism resulting in a
cluster-wide deregulation remains unexplored.
Here, we explore the potential role of C14 miRNAs
as an essential part of the cellular network and possible
underlying mechanisms in human cancers upon its
deregulation. Our study revealed that the entire C14
miRNA cluster functions as a potential tumor-suppressor
locus in GBM and very likely, in multiple human cancers.
Results and discussion
Analysis of miRNA expression was performed in 1423
samples from seven cancer types for more than 1000
miRNAs using the available data sets from The Cancer
Genome Atlas (TCGA, NIH, USA) on microarray and
next generation sequencing platforms. Initial findings
were validated by real-time PCR for 112 miRNAs in
GBM samples. In addition, mRNA expression profiles
and methylation profiles were analyzed for the entire
GBM panel available on the TCGA server. To the best
of our knowledge this is the largest genomic study
establishing the coordinated function of C14 miRNAs.
The C14 miRNA targets are enriched in genes involved in
glioma
For each miRNA of C14 we predicted target mRNAs using
two independent softwares and their intersection was
selected for further studies. These consisted of 28714
predicted target sites for 7944 genes [Additional file 1].
Pathway enrichment of the predicted target genes revealed
‘glioma’ to be one of the most significantly enriched path-
way (p<3.77x10-6, FDR<0.005) (Figure 1, Additional file 2).
Predicted target genes encompassed 42 out of the
previously known 63 glioma genes (http://www.genome.
jp/kegg/pathway.html). Out of these, 32 glioma pathway
genes are depicted in Figure 1 along with their regulating
miRNAs. We observe that 23 genes are targeted by 26
miRNAs from this cluster. The miRNAs significantly
downregulated in GBM are marked green on Figure 1. It
is intriguing to note that some C14 miRNAs target several
genes of Glioma pathway while some Glioma pathway
genes are the targets of several C14 miRNAs. For example,miR-134 (#18 in Figure 1), significantly downregulated in
GBM, targets eight genes in this pathway according to our
analysis. MiR-134 is a brain-specific microRNA and
already have proven roles in hippocampal neurons [17], in
higher brain functions such as memory formation [18]
and also in differentiation of embryonic stem cells [19].
Further research is needed to explore whether miR-134 is
one of the crucial (‘hub’) C14 miRNA regulating important
biological pathways. Amongst the target genes, majority of
them are targeted by more than one miRNA from C14;
PI3K and AKT genes are targeted by seven different
miRNAs from the cluster. As depicted in the Figure 1, three
and four miRNAs out of the seven are significantly
downregulated in GBM for AKT and PI3K, respectively. It
is likely, that some of these targets are false positives but it
is intriguing that ~72% of the genes in this pathway are
targeted by 50% of the miRNAs (26/52) from C14.
The C14 miRNA cluster is downregulated in GBM
Genome-wide miRNA expression profile for 534 miRNAs
in 496 GBM samples revealed 85 and 95 miRNAs to be
downregulated and upregulated, respectively (Add-
itional file 3). Hence this data-set does not show any
bias towards a general up- or downregulation of
miRNA expression in GBM, in contrast to earlier reports
in cancer [20,21]. Out of the 38 miRNAs from C14
(for which data was available), >68% (26/38) showed
significant downregulation in GBM patients; none were
significantly upregulated (Figure 2). This accounted for
30% of the total downregulated miRNAs (26/85) from the
entire genome. To exclude the possibility of this being a
chance finding, the analyses were repeated with ten random
sets of miRNAs (38 in each set) for the same samples.
These miRNAs were chosen excluding the C14 miRNAs.
The number of downregulated miRNAs ranged between 3
to 9 out of 38 (95% CI, 4.56-7.03), which were significantly
lower than the observation in C14 cluster (26 out of 38,
p<10-10) (data not shown).
For experimental validation of the results described
above we performed real-time PCR on 43 miRNAs
from C14 in brain RNA of GBM patients and controls. As
depicted in Figure 3A, the overall expression of tested C14
miRNAs is lower in GBM. Our data shows 79% (34/43)
of C14 miRNAs with at least 40% downregulation in
GBM (Figure 3B, Additional file 4). To test robustness
of our assay we also inspected 69 miRNAs from out-
side the C14 cluster with previously known altered
expression in GBM and produced the expected alter-
ation [22] (both up and down) in 42 of these miRNAs
(61%; Additional files 4 and 5). Thus, an independent
quantitative estimation of miRNA expression confirmed
downregulation of essentially the entire cluster of C14
miRNAs in GBM. The results indicate that majority of
the miRNAs in C14 regulate the glioma pathway and a
Figure 1 C14 miRNAs target the glioma pathway. The biological process has been drawn by adapting the information from the KEGG pathway.
mRNA names are written in dark grey boxes. The miRNAs targeting the corresponding genes are denoted by numbers and written inside circles. The
miRNAs that were found to be significantly downregulated in GBM (Figure 2) has been colored in green, the ones not differentially expressed are in
grey. The miRNAs are numbered according to their respective positions (5’ – 3’ direction) in the genome: hsa-miR-379 (1), -299-3p (2), -380 (3), -1197
(4), -323-3p (5), -323-5p (6), -323b (7), -758 (8), -329 (9), -543 (10), -495 (11), -654-3p (12), -654-5p (13), -376-a1 (14), -376-a2 (15), -539 (16), -382 (17), -134
(18), -668 (19), -485-3p (20), -485-5p (21), -377 (22), -541 (23), -409-3p (24), -409-5p (25), -412 (26).
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cause a major systemic perturbation. Whether the
observed downregulation is actually a cause of the systemic
perturbation or it’s an effect of another global perturbation
will be revealed by further studies. It is interesting to note
that miR-379 from C14 has four other family members lo-
cated in the same cluster (http://www.mirbase.org/cgi-bin/
mirna_summary.pl?fam=MIPF0000126). Majority of these
members were found amongst the downregulated C14
miRNAs in GBM. It remains to be seen whether studying
the miRNAs belonging to the same family (may or may not
be in the same cluster) can give us more insight into their
biology, especially when an additive effect of many miRNAs
is investigated.
An earlier study of the corresponding cluster in mice
has provided evidence that most, if not all, pre-miRNAs
are generated through RNA processing from polycistronic
RNA rather than being individually expressed asprimary transcripts [23]. Another study demonstrates
that this cluster is expressed as a polycistronic unit in
rat [13], which corroborates with our aforementioned
results showing coordinated downregulation. The C14
miRNAs are reported to have enriched expression in
brain [23], which signifies our observed altered expres-
sion in GBM, the most aggressive form of brain tumor,
which accounts for 52% of all primary brain tumor cases
and 20% of all intracranial tumors [MIM: #137800].
Interestingly, the 14q32 locus, encompassing a much larger
region of ~20 Mb had been predicted to harbor a tumor
suppressor gene in relation to GBM as multiple studies
reported loss-of-heterozygosity (LOH) or hypermethylation
at this region in glioma patients [24-26]. The probes used
in these studies to detect LOH are of a lower resolution
and the actual probe site is outside the miRNA cluster. It
would be important to carry out future studies by probing
the actual cluster region for LOH studies in GBM.
Figure 2 Downregulation of C14 miRNA cluster in GBM. On the Y-axis the difference of the median normalized expression levels between GBM
and controls (Median_GBM – Median_Control) are plotted for each miRNA (X-axis). Negative values indicate lower expression in GBM. The miRNAs from
left to right are,MiR-379, 411, 299-3p, 299-5p, 380-3p, 380-5p, 323, 758, 329, 494, 495, 376a, 376a*, 654, 376b, 381, 487b, 539, 544, 655, 487a, 382,
134, 668, 485-3p, 485-5p, 453 (323b), 154, 154*, 496, 377, 409-3p, 409-5p, 412, 369-3p, 369-5p, 410 and 656. Green bars indicate significant
downregulation in GBM after genome-wide Bonferroni correction (miR names are in bold above). Grey bars indicate expression changes that are not
significant post correction. The normalized data were obtained from the TCGA server. Mann-Whitney U test was applied to analyze differential expression.
A p value less than 0.05 (post correction) is considered significant. As seen in the figure for the entire cluster (on the horizontal axis) the miRNAs were
significantly downregulated in GBM pointing to a coordinated situation.
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Genome-wide methylation status of 76 GBM samples
were obtained from the TCGA server (Human Methylation
450K bead chip, Illumina) and tested for the methylation
status of the genomic region encompassing the miRNA
cluster (~60 Kb) by calculating the beta-values. The
Beta-value is the ratio of the methylated probe intensity and
the overall intensity (sum of methylated and unmethylated
probe intensities). A value of >0.8 and <0.2 is usually con-
sidered hyper- and hypo-methylation, respectively [27]. We
found that C14 is significantly hypermethylated (p <0.003),
having a median beta-value of >0.8 (Figure 4). We have
selected a larger imprinted miRNA cluster on chromosome
19 (C19 in Figure 4) as a control region to study methyla-
tion in GBM. The methylation at C14 was significantly
higher than that in C19. We excluded the possibility
that observed hypermethylation of C14 is a random
chance by analyzing 10 random regions from the genome.
The methylation level of these random regions were
within the normal range and comparable with the C19
methylation pattern. As hypermethylation is usually
associated with repression of transcription, this can be
the causal factor for suppressed expression of the entire
cluster in GBM. Genomic coordinates for C14, C19 and
10 random regions are listed in Additional file 6.
The C14 transcription factor MEF2 is downregulated in GBM
As mentioned in the introduction, Mef2 has been reported
as the necessary transcription factor for C14 and hence
expression of four family members of MEF2 was examined
in 593 GBM samples (transcriptomic data from TCGA).Significant down-regulation of MEF2A and MEF2C was
found after Bonferroni correction (Figure 5A; two-
tailed Mann-Whitney U-test, p values 0.0017 and 0.0011,
respectively). Further, we performed real-time PCR analysis
of MEF2 transcripts in eight GBM samples and six controls
(Figure 5B) and found significant down-regulation for
MEF2A (p=0.009) andMEF2C (p=0.04).
The hypermethylation of C14 and the downregulation
of MEF2 can be the cause of observed C14 miRNA
downregulation in GBM independently or in synergy. As
mentioned earlier, Mef2 has been shown to positively
regulate transcription of C14 in rat neurons where silencing
of Mef2 results in switching off the miRNA expression [13].
MEF2 has an established role in neuronal function and
some studies reported its link to cancer. Notch-Mef2
synergistic overexpression results in increasing cellular
proliferation and metastasis in drosophila and had higher
chance of relapse in human breast cancer patients [28].
Studies in mice have shown Mef2c accelerating myeloid
leukemia induced by Sox4 [29]. However, role of MEF2 in
human cancers remains largely unexplored and our data
indicate that it might have a major role in the pathogenesis,
especially in case of GBM.
C14 miRNAs are downregulated in other human cancers
We compared the expression of C14 miRNAs in three
different cancers excluding GBM, to check the possibility
that the downregulation of C14 miRNA cluster is not con-
fined to GBM alone and is general to neoplastic processes.
In all cancer types C14 miRNAs accounted for 12-20% of
the total downregulated miRNAs (Figure 6 and Additional
Figure 3 (See legend on next page.)
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Figure 3 Real-time PCR validation of C14 downregulation in GBM. A) The heat map shows the fold changes (calculated by ΔΔCt method) of
the respective miRs of C14 in 3 GBM cases with respect to the controls. Fold change <= 0.6 is taken as down-regulation (green) and >=2 is taken
as upregulation (red), whereas, the intermediate values are considered to have non-differential expression (yellow) between the samples. As
depicted for all the three GBM samples, 79% (34/43) of C14 miRNAs were found to be >40% downregulated in GBM. B) The box plots show the
median distribution of ΔCt values of the C14 miRs in each of the sample. The GBM samples show distinctive lower median value as compared to
the controls. The jitter-plot shows the total data distribution (ΔCt) in each sample.
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in KIRC, 46% in BRCA and 14% in OV. This proportion
was significantly higher (p<10-20 for BRCA, GBM & KIRC
and p<0.002 for OV) than expected by random chance
(3-5%). These results along with the existing literature
strongly suggest that this is a tumor suppressor locus
important in general physiology. Our results corroborate
the earlier reports wherein deregulation of members of
C14 miRNA cluster has been identified in different human
diseases. Our study has systematically analyzed the
possibility that the entire cluster is in fact functioning
like one transcription unit and its deregulation in cancer
can be possibly attributed to its altered methylation status
and/or repression of transcription factor MEF2.Figure 4 Hypermethylation of C14 in GBM. R1 to R10 represent
10 random regions of the genome having similar number of
methylation probes as that of C14 (~200 probes). We have used
another imprinted microRNA region, present on Chr19, as a control
(C19) to test the specificity of the methylation pattern on C14 in
GBM. The relative methylation levels are plotted along the vertical
axis (beta values). The jitter plots in the background represent the
total distribution of the beta-values in each region for all samples.
The box plots determine the median beta-values of those regions.
C14 is found to be hypermethylated having median beta-value >0.8
(p<0.003), whereas the other sets, including C19 are random in
distribution within the normal range (0.2 to 0.8).Conclusion
Our study shows that the entire miRNA cluster miR-
379/miR-656 comprising of more than 50 miRNAs is
downregulated in multiple human cancers. We have also
shown that in GBM, the genomic region harboring this
cluster is hypermethylated and the required transcription
factor is significantly downregulated. In summary, we
propose the entire miR-379/miR-656 cluster on humanFigure 5 C14 transcription factor MEF2 is downregulated in
GBM. A) Y-axis shows expression levels of different MEF2 isoforms.
“C” and “P” represent controls and patient data, respectively. The
median expressions of the different isoforms are distinctly lower in
GBM (green) than the control samples (red). The normalized
expression values were fetched from the TCGA server. B) Real-time
PCR validation of MEF2 expression. Y-axis shows different isoforms of
MEF2 and X-axis shows 8 GBM samples. Fold change <= 0.6 is taken as
down-regulation (green) and >=2 is taken as upregulation (red),
whereas, the intermediate values are considered to have non-differential
expression (yellow) between the samples (relative to data from six
controls). Significant downregulation was found for MEF2A (p = 0.009)
and MEF2C (p = 0.04) by Mann-Whitney U test on ΔCt values.
Figure 6 C14 miRNAs are downregulated in other human cancers. For each cancer type the total miRNA expression and the number of
miRNAs downregulated are shown both for the C14 cluster and the entire miRnome. On the Y-axis the different numbers has been normalized
to 100%. The fraction marked in green demarcates the proportion of miRNAs downregulated (significant after Bonferroni correction) against all
miRNAs tested (in grey). As depicted in the figure for all the cancer types (albeit less for OV) the proportion of downregulated miRNAs from C14
is much higher than that from the miRnome (green bars). The detailed data and analysis is in Additional file 6. GBM, Gliobalstoma Multiforme; OV,
ovarian serous cystadenocarcinoma; BRCA, Breast invasive carcinoma and KIRC, Kidney renal clear cell carcinoma.
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cancer and suggest a general mechanism of coordinated
functioning for large polycistronic miRNA clusters.
Methods
miRNA target prediction
A local database containing the 3′-UTR sequences for
all human genes (NCBI build 36) were made using the
publicly available data in ensemble 54 (http://www.ensembl.
org/index.html).
To predict targets for each of the 52 mature miRNAs,
we have used two independent prediction tools, namely,
miRanda (Sep 2008) and TargetScanS 5.1. Default parame-
ters were used for both the tools.
From the two separate lists of predicted targets generated
by miRanda and TargetScanS, we have built a consen-
sus list of targets using Perl. We have included a target
site only when the genomic co-ordinates were identical
in both the predictions. Any 3′-UTR that are predicted
targets of the same miRNA in both but at different
positions was excluded from the consensus list to reduce
false positives.
Pathway analysis with the target genes
To analyze the enrichment of biological process in the
consensus list of target genes, we used the pathway analysis
tool DAVID [30,31]. We have used the default parameters,
e.g., threshold count 2, modified Fisher’s exact test p-value
threshold (EASE score) 0.1. To globally correct enrich-
ment P-values to control family-wide false discovery
rate (e.g., <= 0.05), DAVID provides multiple testingcorrection techniques like Bonferroni, Benjamini and
FDR, which were taken into account during the analysis.
Data mining at the TCGA portal and statistical analyses
The Cancer Genome Atlas (TCGA) data portal (https://
tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) is a comprehen-
sive and coordinated effort to accelerate our understanding
of the molecular basis of cancer through the application of
genome analysis technologies. All our meta analysis
was done using data from the TCGA resource. Below
descriptions are given separately for each type of data.
miRNA expression data and analysis
We have analyzed the genome-wide miRNA expression
from microarray data for 1099 samples including GBM
(496 GBM + 10 control) and ovarian cancer (585 OV +
8 control) and 324 samples from next generation
sequencing of small RNA data which includes Breast
invasive carcinoma (BRCA, 80 tumor and 80 matched
controls), Kidney renal clear cell carcinoma (KIRC, 67
Tumor and 67 matched controls), Stomach adenocarcin-
oma (STAD, 9 Tumor and 9 matched controls), Prostate
adenocarcinoma (PRAD;3 Tumor and 3 matched controls)
and Bladder Urothelial Cancer (BLCA; 3 Tumor and 3
Matched controls). In Additional file 8, the sample IDs for
each sample used in the study has been given. For analysis
we have used the miRNA expression data generated in
Human specific Agilent 8x15k array and Illumina NGS
platform. We extracted the quantile normalized log
transformed data (level 3) for miRNA expression for
all analyses used in this study.
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controls was determined using non-parametric two tailed
Mann-Whitney U test. The test was repeated for each
miRNA and corrected for multiple comparisons by multi-
plying the p value obtained by the total number of miRNAs
tested (Bonferroni correction). Identification of upregulated
and downregulated miRNAs was determined by similar
one-tailed tests. To determine whether the observed pat-
terns of up- or down-regulation was specific to the miRNA
cluster tested; we compared the proportions of upregulated,
downregulated, and similarly expressed miRNAs from C14
with random sets taken from the genome by chi-square test
of proportions. In all cases the p-value threshold was <0.05
(post-correction). For the prostate cancer, stomach adeno-
carcinoma and the bladder cancer datasets, differential ex-
pression was not calculated due to small sample numbers.
Source of genome-wide methylation data and analysis
We fetched the available raw image files of the GBM
methylation data for 76 patients, generated on Infinium
HumanMethylation450K BeadChip (Illumina Inc.), from
the TCGA Data Portal. The experiment was performed
on the DNA samples isolated from the tumor specimen
of each patient. For further analyses, we used minfi
package of Bioconductor (http://www.bioconductor.org/
packages/2.12/bioc/html/minfi.html). This resulted in a
matrix of M-values for the corresponding probes. We
converted the M-values to beta-values, as beta-values
have a more intuitive biological interpretation, using the
formula Betai=2
Mi/(2Mi+1) [27]. Due to the absence of
control samples, we have used 10 random stretches of the
genome and a larger imprinted miRNA cluster on Chr19
(C19), covered by similar number of probes (~200 probes),
to rule out the possibility of the observation for C14 being
a random occurrence. The beta-values of this locus and 10
other random regions were statistically checked for signifi-
cant hypermethylation by the application of one tailed
t-test. The plots were generated using ggplot2 package of R
(http://cran.r-project.org/web/packages/ggplot2/index.html),
where the jitter plot showed the total beta-value distribution
for each region, whereas, the box plots represented the
median values for each region in all the samples.
Source of transcriptome (mRNA) data
We have also analyzed whole genome mRNA expression
data of 593 GBM samples and 10 controls from Agilent
G4502A array on the TCGA data portal and extracted
expression data which is lowess normalized data (level 3).
The downstream analysis was same as described above for
the miRNA.
Sample collection and histopathological analysis
All samples were collected according to the Helsinki
Declaration and the ethical review board of All IndiaInstitute of Medical Sciences, Delhi, India approved
the project. Samples were obtained fresh at the time of sur-
gery and portions were snap frozen in liquid nitrogen and
stored at -80°C until use. Rest of the sample was formalin-
fixed and paraffin-embedded for routine histopathology.
Subsequently, 5 micron sections were cut from the
paraffin-embedded tissue and stained by hematoxylin and
eosin (H&E) stain. Diagnosis and grading were done as per
2007 WHO classification [32].
Frozen tumor specimens were embedded in freezing
medium and 15 serial sections of 40 mm were cut on cryo-
stat and stored immediately in liquid nitrogen cooled vials
for RNA isolation. Flanking sections measuring 5 micron
were then taken and stained by H&E for histological
analysis. The histopathology of each collected speci-
men was reviewed to confirm adequacy of the sample
(i.e., minimal contamination with non-neoplastic elements)
and to assess the extent of tumoral necrosis and cellularity.
The stored sections were used for nucleic acid isolation
only when the flanking H&E sections showed no normal
tissue and the tumor content was more than 80% with no
or very little necrosis. Along with the tumor specimens for
the GBM samples, tissues from six non-GBM samples were
also collected to be used as controls. Five of them were
patients of grade I transitional meningioma where the
supra-tentorial parasagittal sections were collected and
one of them suffered from mesial temporal sclerosis where
the tissue from temporal lobe was used. In the manuscript
these samples has been referred to as controls. For mRNA
(MEF2) expression all six controls were used and for
miRNA real-time PCR, three of the meningioma samples
were used.
Real-time PCR validation of miRNA and mRNA expression
Total RNA was isolated from brain tissue of GBM patients
and controls using the mirVana miRNA Isolation Kit
(Ambion, USA) according to the manufacturer’s protocol.
The quality and quantity of the RNA was determined by
spectrophotometric measurement and gel electrophoresis.
cDNA was synthesized from 400 ng total RNA using
QuantiMir Kit (System Biosciences, USA), as per the
manufacturer’s protocol in a reaction volume of 10 μl.
For real-time quantitative RT-PCR (QPCR), 20x dilutions
of the cDNA were made and 1.0 μl from the diluted stock
was used for each PCR reaction. Forward primers for 43
microRNAs of the C14 miRNA cluster were designed from
the 5′ stem of the mature miRNA and universal reverse
primer was used as supplied by the manufacturer (System
Biosciences, USA). Relative quantitation was performed
using KAPA SYBRW FAST Universal 2X qPCR Master
Mix (KAPA BiosystemsInc, USA). PCR reactions were
performed on a Light Cycler machine (Roche LightcyclerW
480 II, Roche, USA). Duplicate QPCR reactions were
performed for each cDNA to ensure reproducibility.
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expression for the microRNAs. 69 miRNAs having reported
differential expression levels of expression in GBM were
used as positive controls. The mean expression level of
miR-92a was used for normalization [33]. The differences
in expression between patients and controls were calculated
by using the ΔCT method [34].
Total RNA isolation, quality & quantity check was
done exactly same as described above for miRNA. cDNA
was synthesized from 1 μg total RNA using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems), as
per the manufacturer’s protocol in a reaction volume of
20 μl. For QPCR, 10x dilutions of the cDNA were made
and 1.0 μl from the diluted stock was used for each PCR
reaction. Forward primers were designed against exon
junctions and reverse primer from within the exon. Relative
quantitation was performed as before, taking duplicates to
ensure reproducibility. The mean expression level of
B2M [35] was used for normalization. The differences
in expression between patients and controls were calculated
using the ΔCT method [33]. The primer sequences for each
variant are available on request.
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what was done and assess the claims. The manuscriptwould benefit from a rewrite, inserting more information
into the Results and Figure legends.
Response: We have incorporated more information in
the results section and the figure legends as suggested by
the reviewer.
Comment: Figures 2 and 3 shows the downregulation
of many members of the cluster in glioblastomas relative
to controls, but there is no mention of what the controls
are, making interpretation difficult.
Response: In Figure 2 the normalized (level 3) expression
data from TCGA repository has been used to analyze the
miRNA expression difference. As mentioned in the ‘miRNA
expression data and analysis’ section under ‘Materials
and Methods’ the TCGA server provided brain miRNA
expression from 10 control samples. In the revised manu-
script we have added a supplemental file (supplement 7)
with individual samples IDs (TCGA barcodes) for easy
reference. As information provided by TCGA these 10
control samples were brain tissues from 10 unrelated
individuals who did not suffer from GBM.
In Figure 3 we have reported data of real-time PCR for
samples collected by us. Here the three non-GBM con-
trols were patients of transitional meningioma for whom
supratentorial parasagittal sections of the brain were used.
This has now been modified in the revised manuscript in
the section ‘Sample collection and histopathological analysis’
under ‘Materials and Methods’.
Comment: Page 5 “PI3K and AKT genes are targeted by
seven different miRNAs from the cluster” but are these
seven miRNAs among the ones that are down-regulated
in GBM? Figure 1 would be more useful if it included an
indication of which of the C14 cluster miRNAs shown on
the Fig are actually down-regulated in GBM.
Response: We have now modified Figure 1 as suggested
by the reviewer. The miRNAs found to be downregulated
in GBM have been colored in green. We have also modified
relevant sections in the results and the figure legend. As
seen in the modified figure, not all seven miRNAs are
downregulated as reveled by the statistical analysis of
the microarray data. The actual biological cross-talk
will be clear after extensive functional studies for
mRNA:miRNA interactions.
Comment: On Page 9 it is stated that cluster miRs
were downregulated in several cancers at significantly
higher proportion than expected by random chance. The
statisitical test used and the P value should be given.
Response: In all the cancers tested we have found the
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than expected by random chance (Figure 6). The p
values were: p<10-20 for GBM, BRCA and KIRC and
p<0.002 for OV. These were obtained by chi-squared
tests. The details are in supplemental file 6. We have
also added a new figure in the main manuscript with
this data (Figure 6).
Minor correction
Comment: Page 14. “Flanking sections measuring 5
mm were then taken and stained
by H&E for histological analysis.” Was this not 5 um ra-
ther than 5 mM?
Response: We thank the reviewer for pointing out this mis-
take. It has now been corrected in the revised manuscript.
Quality of written English: Acceptable
Reviewer’s response: My comments have been adequately
addressed.
Reviewer’s response: The numbering of Figs in the
published version will need to match the numbering in
the text (currently it does not for Figures 4 onwards).
Author’s Response: We think the confusion about figure
numbering arose from the fact that we have uploaded
two separate files for two panels of Figure 3. So, although
the total number of figures are 6, but 7 files have been
uploaded for figures. We have checked the text in the
manuscript and there are no errors. We hope the two
separate panels can be merged at the publication stage.
Quality of written English: Acceptable
Reviewer's report
Title: Genome-wide analysis reveals down-regulation of
miR-379/miR-656 cluster in human cancers
Versions: 1 & 2 10 December 2012/ 5 March 2013
Reviewer number: 2
Reviewer: Dr Alexander Max Burroughs (nominated by
Dr L Aravind)
Laddha and colleagues mine TCGA data to investigate
the role of a specific miRNA-rich genome region in dif-
ferent cancer types. In addition to uncovering a likely
role for this genome region in GBM, the authors supply
independent experimental data supporting their claims.
Targeted computational analysis of large, publicly-
available datasets can provide fruitful avenues of investiga-
tion for researchers as the large consortiums generating
these datasets often lack sufficient manpower to thoroughly
comb through the data. Along these lines, I find the
manuscript of general interest particularly since this
specific miRNA cluster has not been the subject of
extensive research in the past. However, I have a few
points for the authors to consider:Comment: The examined genomic locus covers many
miRNA, and several of these belong to the same
miRNA family (e.g. miR-379, miR-380, miR-411, miR-758,
and miR-1197 all belong to the same family according to
miRBase). Is it possible the observed downregulation is
largely driven by one or two families being instead of a
locus as a whole? I specifically bring this up because of
another paper implicating members of the above family
in GBM, see Skalsky RL and Cullen BR in published in
September 2011 in Plos One.
Response: We thank the reviewer for his concern. Although
this may be a concern for other regions of the genome but
for the C14 miRNA cluster this issue does not confound our
data. We checked the reference suggested by the reviewer
and found that they have talked about only one family
within the cluster of miR-376 (miR-376a, -b or-c). The other
miRs of this cluster are actually not part of the same family.
Also upon multiple alignment of the pre-miRNA sequences
of the miRNAs from C14 one finds very low similarity
between them pointing to the above fact. Although theoretic-
ally it is still “possible that the observed downregulation is
largely driven by one or two families being instead of a locus
as a whole”; but given all the evidences provided by our
study this is a remote possibility.
Comment: At several points in the paper the authors
compare activity at the C14 locus to randomly-selected
genome regions, but explanations of the criteria determin-
ing selection of these random regions are relatively scant.
In each case are the authors filtering out other miRNA-
rich genomic regions or instead selecting for miRNA-rich
regions? Are they selecting genome regions with similar
characteristics (e.g. similar ratio of coding or non-coding
transcripts, similar ratio of repetitive regions, etc.)? If
instead the authors are simply taking similarly-sized
genomic sequences, I would think that 10 random selec-
tions would not be enough to amass a viable background
set since localized attributes can substantially influence
several of the characteristics being investigated. Since this
selection underlies some of the more crucial findings of
the manuscript, this could be considered more carefully
or at least better-described in the text.
Response: We have used 10 random sets in two different
scenarios in this study. Both are separately described below:
(i) To check that the observed downregulation of C14
miRNAs in cancers is not by chance, we have selected 10
random sets of miRNAs to analyze from the miRNA
expression data. This datasets are not from contiguous
stretches of genome but consists of similar number of
miRNAs as C14 (38 miRNAs randomly selected from
genome excluding C14). As the observed downregulation
is much more than expected by random chance and we
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this finding is unlikely to be a false positive. In addition,
as the total number of miRNAs for which expression data
was available (for GBM) was only 534, more random sets
will actually repeat the same miRNAs across multiple
sets making the analyses redundant. The following text
in the Results section has more specific information:
“To exclude the possibility of this being a chance
finding, the analyses were repeated with ten random
sets of miRNAs (38 in each set) for the same samples.
These miRNAs were chosen excluding the C14 miRNAs.
The number of downregulated miRNAs ranged be-
tween 3 to 9 out of 38 (95% CI, 4.56-7.03), which
was significantly lower than the observation in C14
cluster (26 out of 38, p<10-10)”.
(i) To check the possible altered methylation pattern of
C14 in GBM, we have compared it with the methylation
pattern of another imprinted large miRNA cluster on
chromosome 19 (C19). The other 10 regions are randomly
selected from the genome. The genomic sizes are not
comparable, but the number of methylation probes is
comparable (~200 probes per region) in a contiguous
genomic stretch. The specific coordinates of each region
have been given in the supplementary information. As the
distribution of the probes on the microarray is not uniform
throughout the genome, it is practically improbable to
select enough number of regions with different distributions
of mRNAs, miRNAs, repeats etc.). This section has now
been modified in the revised manuscript.
Comment: The authors use quite a conservative
method for identifying significant miRNA up/down
regulation. Did the authors consider a different method,
for example edgeR in Bioconductor, and how did these
results compare?
Response: edgeR is a tool for analyzing digital gene
expression data generated from NGS platforms, taking
read counts and library size as inputs. The data we
have primarily focused is the GBM dataset, which has
microarray data for which edgeR is unsuitable. The other
cancer types in TCGA, for which we have used small RNA
sequencing data for expression analysis, do not have level
1 data which would have the information required by
edgeR for analysis. The different expression data analysis
tools primarily differ in their method of normalization of
the raw data. As we have used the normalized expression
data from TCGA, we have directly applied statistic to test
differential expression.
Comment: As currently written, the manuscript is
unclear on which cell types were analyzed when examining
methylation patterns. Are these the same as the samples
used for miRNA profiling? Do they match the samecancer type? Perhaps this is evident to those well-versed
with the TGCA dataset but making this clearer would
improve readability.
Response: We thank the reviewer for this constructive
suggestion. The methylation experiment was performed
on the DNA samples isolated from the tumor specimen of
each patient. The data were from 76 GBM samples
which were also included in the miRNA expression analysis.
We have now added a sentence in the relevant section
under ‘Materials and Methods’.
Comment: The authors state “the results compel us to
say that majority [sic] of the miRNAs in C14 regulate the
glioma pathway and a coordinated downregulation of the
miRNAs can cause a major systemic perturbation.” I’m not
sure the analysis presented by the authors determines causa-
tive relationship. It seems quite possible that the opposite
could be true: some systemic perturbation is causing the
downregulation of the miRNAs in this genomic location.
Response: The statement has been modified as follows:
“The results indicate that majority of the miRNAs in
C14 regulate the glioma pathway and a coordinated
downregulation of the miRNAs might cause a major sys-
temic perturbation. Whether the observed downregulation
is actually a cause of the systemic perturbation or it is
an effect of another global perturbation will be revealed
by further studies.”
Comment: While the authors specifically address
upregulation of C14 miRNAs in GBM, how much
upregulation is observed in the other cancer lines?
Response: We actually observed a downregulation
(not ‘upregulation’) of C14 miRNAs in GBM and other
cancers and all the data presented in the manuscript
are from patient tumor samples and not from cancer
lines. The proportion of downregulated miRNAs varied
from 12-30% of all downregulated miRNAs and all cases
were statistically significant. A new figure has been added
in the revised manuscript (Figure 6) to explain the results
and the detailed analysis is in Additional file 6.
Minor point
Comment: In the conclusions, the authors state “…the
required transcription factor is significantly downregulated”.
Are the authors certain MEF2 is the only transcription
factor active in this location?
Response: Given the complex nature of human biology,
it is almost certain that MEF2 is not the only molecule
transcriptionally regulating this cluster. However, it has
been reported in the literature that regulating Mef2
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miRNAs in this cluster implicating Mef2 as the most
important transcription factor for the cluster. Details of
this findings can be found in Fiore R et al, EMBO J.2009;
28:697-710.
Quality of written English: Needs some language
corrections before being published
Response: We have put in sincere efforts to make the lan-
guage better and more accurate in the revised manuscript.
Reviewer’s response: The comment was not intended
to suggest that all of the miRNAs from C14 belong to
the same miRNA family; this is certainly not the case. I was
instead making the observation that mir-379 family mem-
bers (see miRNA gene family mir-379: http://www.mirbase.
org/cgi-bin/mirna_summary.pl?fam=MIPF0000126) are
present in C14 and appear to largely belong to the set
of significantly down-regulated miRNAs; the supplied
reference also found members of this family involved
in GBM. I was wondering if the authors checked the
list of down regulated miRNAs, within and outside of
C14, for the presence of complete (or nearly complete)
families of miRNAs. While I very much appreciate the
author’s detailed responses to the other comments,
particularly the extensive clarifications relating to
methodology, I think this remains a point of interest: if
specific miRNA families are making key contributions
this could aid further studies into target identification,
throwing more light on GBM.
Author’s Response: We thank the reviewer for clarifying
his earlier concern and for providing us information about
the family members. In light of his comment we now have
included a statement in the re-revised manuscript in the
relevant section. The statement is appended below.
“It is interesting to note that miR-379 from C14
has four other family members located in the same
cluster (http://www.mirbase.org/cgi-bin/mirna_summary.pl?
fam=MIPF0000126). Majority of these members were found
amongst the downregulated C14 miRNAs in GBM. It
remains to be seen whether studying the miRNAs belonging
to the same family (may or may not be in the same cluster)
can give us more insight into their biology, especially when
an additive effect of many miRNAs are investigated.”
Reviewer’s response: I apologize as my initial comment
was not very clear: as the authors are surely aware, sev-
eral different methods exist for addressing the multiple
testing problem in both microarray and next-generation
sequencing. Use of the Bonferroni correction is a starkly
conservative choice; I was interested in why the authors
would choose this corrective method over other, morefrequently used methods like FDR. Does a more inclusive
method increase the total number of genes from other
regions in the genome, lessening the “signal” observed
from the C14 region?
Author’s Response: As we had used data generated by
a third party (TCGA), which is also normalized by them,
we wanted to reduce the false positives by using the more
stringent Bonferroni correction. However, we understand
and appreciate reviewer’s concern and have performed FDR
corrections in two of our datasets (namely, GBM & BRCA).
We do not observe a significant alteration of the results.
Specifically, upon application of FDR the data changes as
detailed below:
In case of GBM (microarray platform), the fraction of
C14 downregulated miRs vs. miRNome downregulated
were 0.763 vs. 0.159 (by Bonferroni) and 0.815 vs. 0.204
(by FDR). In BRCA (NGS platform), the C14 downregulated
miRs vs. miRNome downregulated was 0.585 vs. 0.101
(by Bonferroni) and 0.634 vs. 0.154 (by FDR).
For calculating FDR adjusted p values we have run
[p.adjust(<file name>, method=”fdr”)] command in R on
the p-values obtained from Mann-Whitney test and then
taken adjusted p values <0.05.
Since, the change in the data was not altering the
conclusion we did not change the dataset presented in
the manuscript. This analysis was done to take care of
the reviewer’s concern.
Quality of written English: Acceptable
Reviewer’s name: Dr. Yuriy Gusev (reviewer 3)
This reviewer provided no comments for publication.Additional files
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